

**Disclosure Team**

The Association of the British Pharmaceutical Industry  
7th Floor, Southside  
105 Victoria Street  
London  
SW1E 6QT

**Date: 24/03/2019****Disclosure of transfers of value to healthcare professionals and healthcare organisations**

Dear Disclosure Team,

Syner-Med (PP) Ltd. is currently not member of ABPI, however, voluntarily agreed to abide by ABPI Code of Practice in all aspects of commercial and non-commercial activities, particularly interactions with healthcare professionals (HCPs) and healthcare organisations (HCOs). Syner-Med follows the ABPI Code of Practice with regards to any payments (Sponsorships, Registration fee, honoraria etc.) made to HCPs and HCOs in accordance to Clause 1.4, 1.9, 20, 21, 22, 23 & 24.

**METHODOLOGY**

Syner-Med has Policies and Standard Operating Procedures (SOP) in place in line with ABPI Code of Practice, e.g. Sponsorship/Grant Requests, Advisory Boarding, Meetings and Hospitality and all such requests are processed and approved as per relevant policies and SOPs. Honoraria for consultancy work or Advisory Board meetings etc. are calculated on Fair Market Value (FMV) based on HCPs' role, seniority, time (excluding travel times), hourly/daily rates and industry average.

Syner-Med maintains complete record of all sponsorship/grant requests and payment made to HCPs and HCOs. In the disclosure template multiple payments made have been aggregated into one entry for each HCP or HCO. Amount paid are then subdivided into appropriate categories, i.e. sponsorship, registration, honorarium, travel and accommodation expenses.

In column AC – rows 5-6 of the disclosure template, there are no amounts to declare for HCP's for either Sponsorships, Registration, Honorarium or Travel and Accommodation expenses for 2020, this is due to the impacts of Covid 19 within the industry, Syner-Med PP Ltd received no requests for payments that would fall within this category. total amount paid to HCP's for 2020 disclosure is £0.00 .



However, Syner-Med has made total payment's of £2,126.07 to HCOs in 2020 for grants and sponsorships. Payments of £9,010.00 were made to HCO's for non-interventional multicentre prospective audit and for a randomized clinical trial (£57,982.91). All of which have been documented in Research and Development as per Clause 23.2 in column Z – row 50. The total amount of which is £66,992.91.

Should you require any further information in this matter, please do not hesitate to contact me.

Yours faithfully,

Victoria Thompson  
Finance and Compliance Supervisor

Direct Line: 02086556385  
Email: [victoriat@syner-med.com](mailto:victoriat@syner-med.com)

